NASDAQ:RNAC Cartesian Therapeutics Q2 2025 Earnings Results & Report $6.57 -0.42 (-6.01%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$6.60 +0.03 (+0.46%) As of 10/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cartesian Therapeutics beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 7, 2025. The company reported EPS of $0.50 versus the -$0.76 consensus estimate, while revenue of $0.30 million fell short of the $0.77 million estimate by $0.47 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeBefore Market Opens Cartesian Therapeutics EPS ResultsActual EPS$0.50Consensus EPS -$0.76Beat/MissBeat by +$1.26One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCartesian Therapeutics Revenue ResultsActual Revenue$0.30 millionExpected Revenue$0.77 millionBeat/MissMissed by -$473.00 thousandYoY Revenue GrowthN/AUpcoming EarningsCartesian Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile Cartesian Therapeutics Q2 2025 Earnings FAQ Did Cartesian Therapeutics beat earnings estimates for Q2 2025? Cartesian Therapeutics (NASDAQ:RNAC) reported earnings of $0.50 per share for Q2 2025, beating the consensus estimate of -$0.76. The report was announced on Thursday, August 7, 2025. What was Cartesian Therapeutics' revenue for Q2 2025? Cartesian Therapeutics reported revenue of $0.30 million for Q2 2025, against a consensus estimate of $0.77 million. When is Cartesian Therapeutics' next earnings date? Cartesian Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cartesian Therapeutics on the company's earnings history page. Cartesian Therapeutics Earnings HeadlinesCartesian Therapeutics Announces New Employment Inducement GrantsOctober 2, 2026 | globenewswire.comCartesian Reports Positive Phase 2 Retreatment Data For Descartes-08September 29, 2026 | rttnews.comMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. | Crypto 101 Media (Ad)Cartesian's Descartes-08 Shows Durable Responses In Myasthenia GravisSeptember 29, 2026 | rttnews.comCartesian Therapeutics Reports Positive Retreatment Data for Descartes-08 in Generalized Myasthenia GravisSeptember 29, 2026 | quiverquant.comQCartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia GravisSeptember 29, 2026 | globenewswire.comSee More Cartesian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email. Email Address About Cartesian TherapeuticsCartesian Therapeutics (NASDAQ:RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to genetically program a patient’s own T cells with messenger RNA, enabling the development of transiently engineered cell therapies that may be administered without permanent genetic modification. Cartesian’s lead product candidate is Descartes-08, an autologous anti-BCMA CAR T-cell therapy being developed for autoimmune conditions, including generalized myasthenia gravis and systemic lupus erythematosus. The candidate is intended to target antibody-producing plasma cells that contribute to disease activity. Headquartered in Gaithersburg, Maryland, Cartesian conducts clinical development activities and trials primarily through the U.S. healthcare and biotechnology ecosystem. The company became publicly traded under the NASDAQ symbol RNAC following a 2024 business combination with Selecta Biosciences. Carsten Brunn serves as Cartesian’s president and chief executive officer.View Cartesian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
